
Biotechnology major Biocon’s research arm Syngene International on Tuesday made an impressive debut at bourses, surging 18 per cent, over…
The IPO is an offer for sale (OFS) by Biocon of a part of its shareholding in Syngene Syngene International’s…
Biocon reported Q1FY16 net profit Rs 12,620 crore.
In a sharp criticism of regulator Sebi’s new insider trading norms, industry leader and Biocon chief Kiran Mazumdar Shaw today…
Biocon’s biosimilar strategy is playing out well and the company is set to enter developed or regulated markets with a…
Biotechnology major Biocon today reported 23 per cent growth in consolidated net profit at Rs 126 crore for the quarter…
The price band for the offer has been fixed between Rs 240 and Rs. 250 per equity share of Rs…
She is the only India-based business leader featuring on the list
She is the only India based business leader featuring on the list
PEG-G-CSF and Adalimumab enter phase II while patient recruitment for one insulin Glargine phase II study is complete Biocon has…
Biotechnology firm Biocon on Thursday reported a 78.22 per cent jump in consolidated net profit at Rs 201.54 crore for…
For FY15, Biocon reported a net profit of Rs 497 crore, recording growth of 20% over FY14. Revenue rose 7%…
Research services subsidiary Syngene delivers 27 per cent growth
Offer allows Biocon to monetise its shareholding in Syngene
Biocon on Tuesday said it would sell up to 11% in its contract research arm Syngene in the upcoming IPO.
To focus on improved strategies to catapult the industry to new heights
The combined market for Insulin Glargine in Mexico is estimated to be in excess of $40 million